Literature DB >> 17159987

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Andrew T Parsa1, James S Waldron, Amith Panner, Courtney A Crane, Ian F Parney, Jeffrey J Barry, Kristine E Cachola, Joseph C Murray, Tarik Tihan, Michael C Jensen, Paul S Mischel, David Stokoe, Russell O Pieper.   

Abstract

Cancer immunoresistance and immune escape may play important roles in tumor progression and pose obstacles for immunotherapy. Expression of the immunosuppressive protein B7 homolog 1 (B7-H1), also known as programmed death ligand-1 (PD-L1), is increased in many pathological conditions, including cancer. Here we show that expression of the gene encoding B7-H1 increases post transcriptionally in human glioma after loss of phosphatase and tensin homolog (PTEN) and activation of the phosphatidylinositol-3-OH kinase (PI(3)K) pathway. Tumor specimens from individuals with glioblastoma multiforme (GBM) had levels of B7-H1 protein that correlated with PTEN loss, and tumor-specific T cells lysed human glioma targets expressing wild-type PTEN more effectively than those expressing mutant PTEN. These data identify a previously unrecognized mechanism linking loss of the tumor suppressor PTEN with immunoresistance, mediated in part by B7-H1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17159987     DOI: 10.1038/nm1517

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  608 in total

Review 1.  Universes collide: combining immunotherapy with targeted therapy for cancer.

Authors:  Jennifer A Wargo; Zachary A Cooper; Keith T Flaherty
Journal:  Cancer Discov       Date:  2014-11-13       Impact factor: 39.397

Review 2.  Immunotherapy for primary brain tumors: no longer a matter of privilege.

Authors:  Peter E Fecci; Amy B Heimberger; John H Sampson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

3.  Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.

Authors:  Courtney A Crane; Brian J Ahn; Seunggu J Han; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

4.  Inhibitors of B7-CD28 costimulation in urologic malignancies.

Authors:  R Houston Thompson; Eugene D Kwon; James P Allison
Journal:  Immunotherapy       Date:  2009-01       Impact factor: 4.196

Review 5.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

6.  PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.

Authors:  Melanie Boxberg; Katja Steiger; Ulrich Lenze; Hans Rechl; Rüdiger von Eisenhart-Rothe; Klaus Wörtler; Wilko Weichert; Rupert Langer; Katja Specht
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

7.  Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

Authors:  Richard W Joseph; Mansi Parasramka; Jeanette E Eckel-Passow; Dan Serie; Kevin Wu; Liuyan Jiang; Krishna Kalari; R Houston Thompson; Thai Huu Ho; Erik P Castle; John Cheville; Eugene D Kwon; E Aubrey Thompson; Alexander Parker
Journal:  Cancer Immunol Res       Date:  2013-08-29       Impact factor: 11.151

Review 8.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

9.  IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.

Authors:  Wei Xiao; John D Klement; Chunwan Lu; Mohammed L Ibrahim; Kebin Liu
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

10.  The role of STAT3 activation in modulating the immune microenvironment of GBM.

Authors:  Alfred P See; James E Han; Jillian Phallen; Zev Binder; Gary Gallia; Fan Pan; Dilini Jinasena; Christopher Jackson; Zineb Belcaid; Sung Jin Jeong; Chelsea Gottschalk; Jing Zeng; Jacob Ruzevick; Sarah Nicholas; Young Kim; Emilia Albesiano; Drew M Pardoll; Michael Lim
Journal:  J Neurooncol       Date:  2012-10-25       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.